Cargando…
非小细胞肺癌MET基因突变的机制及靶向药物研究进展
Mesenchymal-epithelial transition factor (MET) gene is an important tumor driver gene of non-small cell lung cancer (NSCLC). Drugs targeting MET 14 exon skipping mutation bring new hope to patients. MET inhibitors that are currently on the market or are about to be marketed include: crizotinib, cabo...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406436/ https://www.ncbi.nlm.nih.gov/pubmed/32702795 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.32 |